Small ubiquitin-related modifiers (SUMOs) conjugated or bound to target proteins can affect
protein trafficking, processing and solubility. SUMOylation has been suggested to play a role …

Accumulation of amyloid-β peptide (Aβ) is a pathological hallmark of Alzheimer's disease
(AD). We have previously demonstrated that electrophysiological and neurotoxic effects of …

Scientists working in the fields of Alzheimer's disease and, in particular, cognitive enhancers
are very productive. The review “Cognitive enhancers (nootropics): drugs interacting with …

Alzheimer's disease (AD) is characterized by neurofibrillary tangles, amyloid plaques, and
neurodegeneration. However, this pathology is preceded by increased soluble amyloid beta …

Abstract Type II diabetes (T2D) has been identified as a major risk factor for the development
of Alzheimer's disease (AD). Interestingly, both AD and T2D have similar characteristics …

Research evidence indicating common metabolic mechanisms through which type 2
diabetes mellitus (T2DM) increases risk of late-onset Alzheimer's dementia (LOAD) has …

G-protein-coupled receptors (GPCRs) are shown to be involved in Alzheimer's disease (AD)
pathogenesis. However, because GPCRs include a large family of membrane receptors, it is …

The aged brain may be used as a tool to investigate altered metabolism of amyloid beta
protein (Aβ42) that may have implications in the pathogenesis of Alzheimer's disease (AD) …

We have explored the potential neuroprotective effect of local lentiviraly-mediated
overexpression of nerve growth factor (NGF) on in vivo long-term potentiation (LTP) in the rat …

Alzheimer's disease affects millions of people, yet, there are only a limited number
approaches for it pharmacological treatment. Thus, identifying factors that decrease the risk …